ASTH vs PCRX

ASTH's Piotroski F-Score of 6/9 indicates a stable but not strong financial foundation, with notable weaknesses in profitability and cash flow generation. The absence of an Altman Z-Score raises concern about default risk, particularly given a high debt/equity ratio of 1.96 and negative earnings growth of -97.7% YoY. While the company exhibits explosive revenue growth (99.7% YoY) and strong earnings surprises in recent quarters, these are not sustainable without improving margins and profitability. The stock trades at a forward P/E of 9.64 but a current P/E of 107.00, suggesting a massive valuation disconnect that reflects overpricing relative to current earnings. The Graham Number of $8.19 and intrinsic value of $1.33 imply severe overvaluation, with the current price of $20.33 trading at a significant premium.

PCRX exhibits a stable but mediocre Piotroski F-Score of 4/9, indicating a lack of strong fundamental momentum. The stock is severely overvalued relative to its deterministic baselines, trading at $23.86 despite a Graham Number of $7.79 and an Intrinsic Value of $1.12. While the balance sheet remains liquid with a current ratio of 4.54, the company is facing a crisis in profitability with earnings growth plummeting by 88.40% YoY. The massive discrepancy between the trailing P/E (149.12) and forward P/E (6.83) suggests the market is pricing in a recovery that is not yet supported by current growth metrics or insider activity.